Genetic Polymorphism and Parkinson's Disease in Taiwanese

Parkinson's Disease Clinical Trial

Official title:

Association Analysis of Single Nucleotide Polymorphisms and the Incidence of Parkinson's Disease in a Hospital-based Case-control Study in Taiwan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01996878
• Other study ID #: CCH060105
• Status: Completed
• Phase: N/A
• First received: November 22, 2013
• Last updated: November 22, 2013
• Start date: February 2006
• Est. completion date: October 2013

Study information

• Verified date: November 2013
• Source: Changhua Christian Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

To observe and analyze the correlation between Single Nucleotide polymorphisms (SNPs) and the incidence of Parkinson's disease in Taiwanese.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 334
• Est. completion date: October 2013
• Est. primary completion date: February 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of Parkinson's disease (case subjects are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)

• Healthy volunteers without Parkinson's disease

Exclusion Criteria:

• Cases showing atypical features, including multiple system atrophy and progressive supranuclear gaze palsy, or secondary causes of Parkinsonism, such as neuroleptic drugs, infection, tumor, previous cerebrovascular accident and known toxins

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Locations

Country	Name	City	State
Taiwan	Department of Neurology, Chang-Hua Christian Hospital	Chang-Hua

Sponsors (1)

Lead Sponsor	Collaborator
Changhua Christian Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	single nucleotide polymorphisms in certain candidate genes		2 weeks	No